Autonomix Medical, Inc. Files Amended Annual Report on Form 10-K/A: Key Insights for Investors
Overview
Autonomix Medical, Inc. (“Autonomix” or “the Company”), a medtech company headquartered in The Woodlands, Texas, has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2026. This amendment, submitted to the U.S. Securities and Exchange Commission (SEC) on June 15, 2026, provides additional information previously omitted from the original filing, specifically addressing Items 10 through 14 of Part III of Form 10-K, including details about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and accounting fees and services.
Key Points in the Report
- Amendment Purpose: The amendment furnishes information omitted from the original 10-K under General Instruction G(3), fulfilling SEC requirements for Items 10–14.
- Restatements and Error Correction: The amended filing explicitly acknowledges that the financial statements reflect the correction of an error to previously issued financial statements. However, it clarifies that these corrections did not require a recovery analysis of incentive-based compensation, nor do they constitute a restatement necessitating clawbacks under SEC Rule 10D-1.
- Corporate Governance: The amendment details the structure of the Board and its committees, highlighting the independence and expertise of its audit committee and the adoption of robust policies such as the Insider Trading Policy and Anti-Hedging Policy.
- Executive Compensation and Ownership: Extensive tables and narrative disclose executive compensation, option and award grants, and the beneficial ownership of directors, officers, and principal shareholders.
- Legal Certifications: The amendment includes new certifications from the principal executive officer and principal financial officer, as required by Section 302 of the Sarbanes-Oxley Act, confirming the accuracy and completeness of the filing.
Potentially Price-Sensitive Information
- Restatement of Financial Statements: The Company has corrected errors in previously issued financial statements. While these corrections are acknowledged, the amendment stresses that they do not rise to the threshold of requiring incentive compensation clawbacks. Still, restatements can be a material factor for investors and warrant close scrutiny of the nature and magnitude of the corrections.
- Public Float and Outstanding Shares: As of September 30, 2025, the public float was reported at \$6,307,279. The number of shares of common stock outstanding as of June 10, 2026, was 11,409,344. These figures impact market capitalization and may affect trading dynamics.
-
Company Status and SEC Filings Compliance:
- Autonomix Medical is not a “well-known seasoned issuer”, nor an accelerated or large accelerated filer. The company is a “smaller reporting company” and an “emerging growth company”.
- The company confirms timely filing of all required SEC reports and compliance with interactive data requirements.
-
Board and Governance Policies:
- The Board has adopted a code of ethics and an insider trading policy applying to all directors, executive officers, and employees. The code of ethics is publicly available and any waivers or amendments will be disclosed.
- Anti-hedging policies prohibit directors, officers, and employees from entering into transactions designed to hedge or offset decreases in the market value of the company’s equity securities without prior approval.
-
Audit Committee and Governance:
- The audit committee is composed entirely of independent directors with financial literacy, including an “audit committee financial expert.”
- The committee oversees all matters related to the Company’s auditors, reviews internal controls, financial reporting, and executive compensation, and manages procedures for handling complaints regarding accounting issues.
-
Compensation Policies:
- Compensation policies are reviewed for potential risk, with the Company asserting that current practices do not pose material adverse risks to the business.
- Equity awards are not timed in anticipation of material nonpublic information or in relation to SEC filings to avoid any appearance of impropriety.
-
Shareholder Rights and Communications:
- Procedures for shareholder communications and director nominations are outlined, with physical mail required for Board correspondence.
-
Related Party Transactions:
- Disclosures on related party transactions and director independence are included, with the Board’s Nominating and Corporate Governance Committee responsible for oversight.
Details for Shareholders and Investors
- Restatement Recoupment Policy: The Company references its Restatement Recoupment Policy (clawback policy), as required by SEC rules, though it notes that the current restatement did not trigger a clawback event.
- Executive Compensation and Equity Grants: Detailed breakdowns are provided for salaries, options, and incentive compensation for the CEO, CFO, and other named executive officers. Equity compensation plans and their approval status are also disclosed.
- Legal Certifications: Principal executive and financial officers have certified the accuracy of the filing, as required by law.
- Section 16(a) Compliance: The Company confirms that all directors, executive officers, and significant shareholders have complied timely with SEC Section 16(a) reporting requirements.
Conclusion
Investor Takeaways: The most notable, potentially price-sensitive information is the correction of errors in previously issued financial statements. While these corrections did not necessitate clawbacks or indicate fraud, such restatements can affect investor confidence and may impact the Company’s future market valuation. Investors should review the nature of these corrections in detail and monitor for any further disclosures.
The Company’s governance, compliance, and compensation disclosures demonstrate adherence to regulatory requirements and best practices for emerging growth companies, which may reassure long-term investors about management’s commitment to transparency and ethical conduct.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filing and consult their financial or legal advisors before making any investment decisions. The information is based on the company’s SEC filings and may not reflect the latest developments affecting the company.
